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Abstract: This study concerns the supercritical antisolvent process which allows single-step 
  production of 5-fluorouracil (5-FU) nanoparticles. This process enhances the physical 
  characteristics of 5-FU in order to deliver it directly to the respiratory tract. Several mixtures 
of methanol with dichloromethane, acetone, or ethanol were used for particle preparation, and 
their effects on the physical characteristics of the final products were studied. The conditions of 
the experiment included pressures of 100 and 150 bar, temperature of 40°C, and a flow rate of 
1 mL/min. The particles were characterized physicochemically before and after the process for 
their morphology and crystallinity. In spite of differences in size, the particles were not very dif-
ferent regarding their morphology. The resulting particles were of a regular shape, partly spherical, 
and appeared to have a smooth surface, whereas the mechanically milled particles showed less 
uniformity, had surface irregularities and a high particle size   distribution, and seemed aggregated. 
Particles of 5-FU precipitated from methanol-dichloromethane 50:50 had a mean particle size of 
248 nm. In order to evaluate the aerodynamic behavior of the   nanoparticles, six 5-FU dry powder 
formulations containing mixtures of coarse and fine lactose of different   percentages were pre-
pared. Deposition of 5-FU was measured using a twin-stage liquid impinger and analyzed using 
a validated high pressure liquid chromatography method. Addition of fine lactose improved the 
aerodynamic performance of the drug, as determined by the fine particle fraction.
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Introduction
Lung cancer is one of the most common cancers worldwide, and is associated with 
significant morbidity and mortality. In fact, lung cancer accounts for approximately 
15% of all new cases of cancers, and is the most important cause of cancer-related 
deaths worldwide, with a total death rate exceeding that from colon, breast, and   prostate 
cancers.1 Regardless of the efforts in the conventional treatment of lung cancer by 
surgery, radiotherapy, and chemotherapy, the outcome of treatment for lung cancer 
has not changed dramatically, and the cure rate remains one of the lowest among all 
malignancies.2–4 In chemotherapy, the delivery of an insufficient drug concentration 
to the tumor site after intravenous or oral administration is the probable reason for 
limited efficacy of anticancer agents.5
Targeting chemotherapeutic drugs to the lung via inhalation offers several potential 
advantages over the oral and parenteral routes, ie, higher local drug concentration, 
avoidance of first-pass metabolic degradation in the liver and/or intestines, decreased 
systemic side effects, and the noninvasive nature of administration.5,6 While preclinical 
studies have shown significant antitumor activity of aerosolized drugs, both in primary International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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or metastatic lung cancer as therapeutic or preventive agents, 
inhalation remains minimally explored as a model of drug 
administration for lung cancer treatment.7
5-Fluorouracil (5-FU) is one of the most extensively 
used chemotherapeutic drugs and radiosensitizers, but 
its use has been restricted by its systemic toxicities, ie, 
severe   gastrointestinal toxicities, hematologic side effects, 
and severe bone marrow disturbances.8,9 Intravenous 
  administration of 5-FU results in a large systemic distribution 
with only a small fraction of the dose reaching the site of 
action, while oral delivery is not a realistic option due to low 
and variable bioavailability. There would be an immediate 
benefit if the drug could be localized near the cancerous tis-
sue within the lungs, as has been confirmed for other drugs, 
such as doxorubicin, melphalan, and floxuridine.10 The direct 
delivery of 5-FU to the lung as an aerosol could maximize 
the local concentration, while minimizing the concentration 
of 5-FU in the rest of the body.11–14
For aerosol delivery of pharmaceuticals to the lung, 
a   narrow size distribution of fine particles is necessary.15 
Several conventional methods are currently being used 
to produce fine powders, including milling, spray-drying, 
recrystallization using solvent evaporation, and liquid antisol-
vents. However, all these techniques have their own specific 
disadvantages. Production of contaminant-free micro- and 
nanoparticles with controlled particle size and desired prod-
uct qualities in an environmentally responsible manner will 
continue to be a major challenge.16
Supercritical technology is increasingly anticipated to 
become an alternative to many conventional processes. In 
the last few years, there has been a rapid increase in use of 
supercritical fluids (SCFs) for particle engineering. The use 
of SCFs has provided a more controlled and tunable method 
to produce a variety of drug delivery systems, whereby many 
of the problems associated with traditional techniques are 
avoided. The advantages conferred by SCFs come from both 
their property and process characteristics, a comparatively 
mild operating temperature, and the dryness and purity of 
the produced particles, making the supercritical approach 
particularly attractive for pharmaceutical applications.17,18
The principal aim of this study was to improve the physi-
cal characteristics of 5-FU via formation of SCF-processed 
nanostructures. In this process, supercritical carbon dioxide 
(SC-CO2) was used both for its chemical properties and as a 
“spray enhancer” with a mechanical effect, whereby a nozzle 
with two coaxial passages allowed introduction of SC-CO2 
and a solution of 5-FU into the particle formation vessel 
where pressure and temperature were controlled.
To the best of our knowledge, the preparation of 5-FU 
as an anticancer drug in the form of nanoparticles by use 
of supercritical antisolvents and preparation of dry powder 
inhalation of the drug has not been reported. In this study, 
the effect of the solvents on the production of the polar 
antitumor drug, 5-FU, was studied in different conditions. 
Dry powder inhalers were then produced from nanopar-
ticles, and the aerodynamic behavior of the nanoparticles 
was evaluated.
Materials and methods
Materials
The 5-FU (USP) was purchased from Alpha Aesar 
(  Germany). The CO2 (99.99%) was obtained from Sabalan 
Co. (Iran). Alpha-lactose monohydrate (Pharmatose® 80) was 
supplied by DMV International (The Netherlands). Solvents 
  including methanol, ethanol, acetone, and dichloromethane, 
all of high-pressure liquid chromatography grade, were 
obtained from Merck Chemical Co. (Germany). All aqueous 
solutions were prepared using distilled water.
Methods
Preparation of 5-fluorouracil nanoparticles  
using supercritical antisolvents
The technical details of the apparatus used in this study 
have already been described elsewhere.19,20 The experiments 
began by delivering CO2 after passing it through a cooling 
device to the precipitator (a vessel with an 0.4 L internal 
volume) by a syringe pump until the desired pressure was 
achieved. The precipitator was placed in an equipped oven 
for exact temperature regulation. The gas entered the pre-
cipitation vessel through a cocentric nozzle placed in the 
upper side of the precipitator until the pressure reached 
100 bar.
Firstly, 5-FU was micronized using a ball mill apparatus 
(F. Kurt Retch MM2000, Germany). Different mixtures of 
organic solvents were selected for preparation of the 5-FU 
solutions (Table 1). Organic solution of drug at a concentra-
tion of 5 mg/mL was delivered through the nozzle at flows of 
1 mL/min and CO2 flow of 20 mL/min. During this process, 
particles were precipitated on a filter located at the bottom 
and on the walls of the chamber. This stage took about one 
hour or so to allow the collection of sufficient solid particles. 
These experiments were completed simultaneously with 
delivery of the drug solution to the chamber. However, 
SC-CO2 was allowed to continue to flow for 20 minutes for 
washing the residual solvents from the chamber. When the 
washing process was completed, the CO2 flow was stopped International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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and the chamber was depressurized down to atmospheric 
pressure.
Physical characterization of nanoparticles
The hydrodynamic diameters of the nanoparticles were 
determined at 25°C by quasi-elastic light scattering using a 
Nanosizer® N4 PLUS (Malvern, England). Samples were sus-
pended in chloroform. The results were expressed as the mean 
hydrodynamic diameter. Results corresponded to the average 
of three determinations and polydispersity index.
The morphology of unprocessed and processed   particles 
was qualitatively assessed using a CamScan MV 2300 
(  Cambridge, England) scanning electron microscope. 
Particles of representative samples were coated with gold-
palladium at room temperature before examination. The 
accelerator   voltage for scanning was 25.0–30.0 kV .
Differential scanning calorimetry was accomplished 
using a DSC-60 (Shimadzu, Japan). Approximately 10 mg 
of the material was placed in an aluminum pan and analyzed 
under dry nitrogen purge. The temperature ranged between 
30°C and 320°C.
Structural analysis of the samples was performed 
using an X-ray diffractometer, Xpert-Pro (Philips, The 
  Netherlands), with a Cu Kα source operating at a tube load 
of each sample assessed between 5° and 80° (2θ) with a 
step size of 0.02°.
Atomic force microscopy topographic measurements were 
performed using a DME DualScope/Rasterscope®   scanning 
probe microscope (DME Co., Denmark). The atomic force 
microscopy studies were performed in AC mode, with a 
spring constant of 2.8 N/m and a resonance frequency of 
100 KHz, a speed of 30–40 µm/s, and a force constant of 
42 N. The processing of topographic or phase images was 
carried out using DME scanning probe microscopy software 
version (DME Co., Denmark). The particles were dispersed 
over an adhesive tape onto a glass slide. Groups of particles 
were located and scanned for their topographic images. The 
scans were done at room temperature.
Preparation of 5-fluorouracil dry powder 
formulations
It has been recognized in several earlier studies that the 
efficiency of a dry powder formulation is highly dependent 
on the size distribution of the lactose carrier used21,22 and the 
content of fine lactose.23 Two binary and four ternary 5-FU 
dry powder inhaler formulations with different fine lactose 
ratios were prepared (Table 2). The 5-FU:carrier ratio was 
1:67.5 (w/w) in all formulations. Alpha-lactose monohydrate 
was sieved manually to produce 63–90 µm fraction carriers. 
Fine lactose was prepared by micronization of alpha-lactose 
monohydrate using an air-jet micronizer (Esco Labor, 
  Switzerland) operating at injecting air pressures of 7 bar, and 
was collected after five passages through the instrument. Fine 
lactose was preblended with coarse lactose for 15 minutes 
before addition of 5-FU to optimize the efficiency of the 
mixing process. The formulations were prepared in a Turbula 
mixer (Dorsa, Iran) at 90 rpm for 30 or 90 minutes. Each 
formulation was manually loaded into size 3 gelatin capsules. 
Fill weight was 15 ± 1 mg, giving a nominal dose of 220 µg 
5-FU per capsule. Following filling, capsules were stored in 
a sealed desiccator over silica gel prior to the experiments. 
The uniformity of the blends was examined by analyzing 
the quantity of 5-FU in 10 capsules, and drug concentration 
assessed using high-pressure liquid chromatography, based 
on the USP 29 monograph for 5-FU. The quantity of drug 
in each capsule was calculated and the content uniformity 
expressed as the relative standard deviation.
In vitro deposition profiles of nanoparticles  
by twin-stage liquid impinger
According to the British Pharmacopeia, the twin-stage liquid 
impinger is a simple, widely used device for evaluation of 
the lung disposition of inhaled particles.24 Four capsules were 
individually installed in a Cyclohaler® device to   analyze each 
formulation. The Cyclohaler was attached to the impinger 
Table 1 summary of operational parameters and particle size of 
processed 5-FU by supercritical antisolvent
Sample Solvent Pressure  
(bar)
Particle  
size (nm)
M1 Methanol 150 2374
M2 Methanol 100 2967
MD1 Methanol-dichloromethane  
50:50
100 248
MD2 Methanol-dichloromethane  
70:30
100 436
MA1 Methanol-acetone 50:50 100 732
MA2 Methanol-acetone 70:30 100 981
Me1 Methanol-ethanol 50:50 100 1987 and 5560
Table 2 Formulations of 5-fluorouracil dry powder inhalers
Formulations Coarse lactose Fine lactose Mixing time 
(minutes)
F1 100% – 30
F2 100% – 90
F3 95% 5% 30
F4 95% 5% 90
F5 90% 10% 30
F6 90% 10% 90International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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which contained 7 and 30 mL of distilled water in stages 
1 and 2, respectively. The capsules were placed inside the 
inhalator and their contents were released by twisting the 
Cyclohaler, and the system was vacuumed to produce air 
streams of 60 L/min for five seconds. After inspiration, the 
twin-stage liquid impinger apparatus was disassembled. 
Thereafter, the thorax, emptied capsules, and each stage 
were washed with appropriate volumes of distilled water then 
  collected into separate volumetric flasks. The total amount (µg) 
of 5-FU recovered from the inhaler, the capsule shells, and 
the upper and lower stages of the twin-stage liquid impinger 
was calculated per four capsules and defined as the recovered 
dose. The fine particle dose was defined as the amount of 
drug recovered per four capsules from the lower stage of the 
twin-stage liquid impinger. The fine particle fraction was cal-
culated as the ratio of the fine particle dose to recovered dose 
and expressed as a   percentage. The   emitted dose was defined 
as the total quantity of drug recovered from upper and lower 
stages of the   twin-stage   liquid impinger per four capsules. 
The 5-FU concentration was assayed by high-pressure liquid 
chromatography according to the USP 29 monograph.
Results and discussion
Preparation of 5-FU nanoparticles  
using supercritical antisolvents
5-FU was recrystallized using supercritical antisolvents and 
the effect of the solvents on improvement of the physical 
characteristics of the particles was studied. 5-FU is a polar 
compound with low solubility in SC-CO2. Among the organic 
solvents, methanol is the main solvent for 5-FU. Therefore, 
methanol was used in combination with dichloromethane, 
acetone, or ethanol to solve 5-FU. The drug was dissolved 
in the mixture of solvents and then the solution was continu-
ously sprayed through a nozzle into the SC-CO2.
The dispersion of solution in the SCF leads to an expan-
sion of the droplets and, at the same time, an extraction of the 
liquid into the fluid occurs. The solvent power of the organic 
solvent decreases dramatically and supersaturation leads to 
the precipitation of particles.25 If a solvent has high solubility 
in CO2, the dissolution of the SCF into the organic solvent 
will be accompanied by a large volume expansion and, as a 
result, a reduction of the liquid density. This will lead to the 
reduction of its solvent power, and therefore, a sharp rise in 
the supersaturation within the liquid mixture. Due to the high 
and uniform degree of supersaturation, small particles with 
a narrow particle size distribution are expected.26
In this study, acetone and dichloromethane were the 
solvents with the highest solubility in SC-CO2 compared 
with methanol and ethanol.27 This difference in the solvent 
properties could be the reason for the marked changes in the 
physical characteristics of the resulting particles.
The level of supersaturation in the mixture of methanol-
ethanol was less than in methanol-acetone, and methanol-
dichloromethane. As a result, particles with bigger sizes 
were observed. In the case of particles precipitated from the 
mixture of methanol-acetone and methanol-dichloromethane, 
it was noticeable that those from methanol-acetone had not 
only a bigger size in comparison with the particles produced 
by methanol-dichloromethane, but also showed more aggre-
gation due to interparticulate bridges (Figure 1). Also, the 
higher proportion of dichloromethane in the combinations 
of methanol and dichloromethane showed marked effects on 
the particle size of 5-FU nanoparticles. This could be related 
to the physical properties of dichloromethane as a solvent 
with high solubility in CO2.
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Figure  1  seM  photographs  of  5-FU  Particles  before  and  after  processing  by 
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Table 1 represents the process conditions based on solvent 
types and proportions. The scanning electron   microscopic 
photographs of the processed 5-FU particles exhibited 
similar morphology, regardless of the process   conditions 
used for precipitation (Figure 1). The 5-FU crystals formed 
were of regular shape, partly spherical, and appeared to have 
a smooth particle surface, whereas the scanning   electron 
microscopic photograph of the milled 5-FU showed a less uni-
form particle shape with surface irregularities.   Furthermore, 
it can be noted that the precipitates obtained at different 
conditions were of different sizes; the particles of 5-FU pre-
cipitated from   methanol-dichloromethane 50:50 (MD1) and 
  methanol-acetone 50:50 (MA1) exhibited a mean particle size 
of 248 nm and 732 nm, respectively, whereas the particles 
from methanol-ethanol 50:50 (ME1) showed two peaks with 
mean particle sizes of 1987 nm and 5560 nm, respectively.
The relatively smooth surface and nonporous texture 
of nanostructured 5-FU particles in the scanning electron 
microscopic photomicrographs correlates appropriately with 
the corresponding high-resolution atomic force microscopic 
image of a small sectional area of a nanosized particle 
  surface. Figure 2 shows a representative surface topographic 
atomic force microscopic image of a supercritically processed 
particle of MD1.
Supercritical processing of pharmaceuticals   generally 
results in the formation of crystalline structures.28 Figure 3 
represents the x-ray diffractometry patterns of the 5-FU before 
and after the process. It illustrates the crystallinity of 
  unprocessed and processed drug, which are qualitatively 
assessed on the basis of the sharpness of the major   diffraction 
peaks. It also indicates that the same pattern of 5-FU has been 
produced by the SCF process.
Differential scanning calorimetry thermographs of 
processed and unprocessed 5-FU particles have confirmed 
the x-ray diffractometry findings. The melting point of 
unprocessed 5-FU was 285.3°C, whereas after processing 
it was 284.3°C–285.0°C. There were no significant changes 
in melting point, suggesting that the solid states of particle 
crystals did not change after the supercritical antisolvent 
process. Figure 4 shows the heat flow with temperature plot 
of 5-FU particles.
The size and surface properties of solid-state particles 
have been shown to play a critical role in the behavior 
of active ingredients in a variety of pharmaceutical solid 
dosage forms. Considering the results from analyzing the 
particle size by scanning electron microscopy, atomic 
force   microscopy, x-ray diffractometry, and differential 
scanning calorimetry, it appears that this supercritical pro-
cessing method was   influential in the preparation of 5-FU 
  nanoparticles. With the results obtained, it is possible to 
conclude that, for this system, the improved operating con-
ditions were for the MD1 formulation, which resulted in the 
formation of regular shapes of the drug crystal nanoparticles 
with smooth surfaces.
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Figure 2 AFM image of a supercritically processed particle of MD1.
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Figure 3 XrD pattern of 5-FU particles before (top) and after (bottom) processing 
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Preparation of 5-fluorouracil  
dry powder formulations
5-FU inhalation is a potential route for the treatment and 
prevention of lung cancer.29,30 In a study published by 
  Tatsumura et al aerosol administration (via nebulization) of 
5-FU to a small group of patients with lung cancer showed an 
antitumor response in 60% of the participants and no adverse 
effects were detected.30 Wattenberg and his colleagues also 
initiated a primary study using 5-FU in the Syrian golden 
hamster. The progression of squamous cell carcinoma in the 
trachea, larynx, and oropharynx was reduced by inhalation 
of nebulized 5-FU.29
Given the treatment potential of lung cancer by aerosol 
therapy, 5-FU dry powder inhaler formulations have been 
prepared (Table 2). Six dry powder inhaler formulations 
with different fine lactose ratios were prepared using the 
MD1 product. Only coarse lactose was used as the carrier in 
formulations F1 and F2. In formulations F3 and F4, 5% fine 
lactose was the third component used and, in formulations 
F5 and F6, 10% fine lactose was used. Two mixing times 
(30 and 90 minutes) were selected for preparation of the 
formulations.
After blending, the content uniformity of the different 
formulations was assessed. The average recovery of 5-FU of 
all formulations in this test was approximately 85%–105%, 
suggesting that the overall mixing, sampling, and analysis 
were satisfactorily accurate. The coefficient of variation (CV) 
in 5-FU content within each formulation was a function of 
the components present and the mixing time. Only formu-
lations F4 and F6 showed a mean content of 5-FU between 
95.5% and 104.5% and a satisfactory mixing uniformity of 
the drug with a CV less than 5%. The mixture prepared by 
mixing coarse lactose with the drug was shown to be the 
least uniform in 5-FU content, with a CV of over 20% for 
F1and 18.7% for F2.
The in vitro deposition profile of the formulations was 
estimated with the twin-stage liquid impinger. The recovered 
dose was 85%–90% for all runs. The emitted doses obtained 
were between 17% (F2) and 43% (F4). The fine particle 
fractions obtained were between 7% for F2 and 21% for F4. 
However, formulations F4 and F6, with a fine particle fraction 
of 21% and 19%, respectively, showed better aerosolization 
behavior compared with formulation F2. In this study the 
superior formulation was F4 with 95% coarse lactose, 5% 
fine lactose, and a 90-minute mixing time, which showed a 
uniform mixing of the particles and carrier (Figure 5), and a 
fine particle fraction of 21%. Figure 6 presents the deposi-
tion percentage of drug in different stages of the twin-stage 
liquid impinger.
Depending on the particle size, shape, and ventilation 
parameters, deposition occurs in all regions of the lung, 
ie, the airways and the alveoli.31 There are three princi-
pal   mechanisms that lead to pulmonary deposition, ie, 
inertial impaction for 5–9 µm particles in large airways, 
gravitational sedimentation for 1–5 µm particles in smaller 
airways and for 1–3 µm particles in respiratory bronchioles, 
and Brownian diffusion in alveoli for #0.5µm particles.32–34 
With decreasing particle diameter below about 500 nm, the 
deposition increases in all regions of the lung because of the 
increasing diffusional mobility.32,35
Conclusion
In the present study, the effects of using several solvents in the 
supercritical processing of 5-FU were evaluated. The results 
showed that marked changes in the physicochemical proper-
ties of the produced particles were possible by this   procedure. 
The sequence of the process was as follows. Firstly, the 
solvents succeeded each other from low   solubility to high 
solubility in SC-CO2, which led to reduction of the particle 
size, in addition to a change in the morphologic   properties 
of the particles. When a solvent has higher   solubility in 
SC-CO2, its solvent power reduces faster in the presence 
of SC-CO2. Therefore, supersaturation happens sooner and 
smaller particles are formed. The particles, subsequently 
were produced, followed by recrystallization of 5-FU from 
methanol-dichloromethane treated nanoparticles character-
ized by relatively smooth surface and narrow particle size 
distribution. In vitro evaluation of the aerodynamic behavior 
of the nanoparticles showed that the respiratory fraction could 
A
100.0 280.0
Temp (C)
B
C
D
E
Figure 4 Dsc thermograph of 5-FU particles: Ball milled A, M2 B, MD1 C, MA1 D, 
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Dovepress 
Dovepress
769
5-FU nanoparticles for pulmonary delivery
increase up to 21% using the mixture of coarse lactose and 
fine lactose as a carrier. Our results could be used as the basis 
for developing 5-FU as an anticancer agent in the form of 
dry powder inhalation through the respiratory route. More 
experimental studies will be carried out to optimize dry 
powder inhaler formulations to obtain more efficient 5-FU 
delivery system to the lung.
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